CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Angion Biomedica Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Angion Biomedica Corp
451 D Street, 5Th Floor
Phone: (857) 209-0050p:857 209-0050 BOSTON, MA  02459  United States Ticker: ELTXELTX
Business Summary
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immuno therapeutics directly to the lymph nodes (brain center) of the immune system. The Company's lead product candidate, ELI-002, is being developed to treat cancers driven by kirsten rat sarcoma (KRAS). It is conducting a Phase I/II clinical trial of ELI-002 (AMPLIFY-201). Its ELI-007, is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers. Its AMP platform has broad potential applications for the treatment or prevention of cancer, infectious diseases and other diseases.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board JulianAdams 69 6/1/2023 6/1/2023
President, Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer, Dire RobertConnelly 64 10/16/2024 6/1/2023
Executive Vice President, Head - Research and Development, Chief Medical Officer Christopher M.Haqq 58 6/1/2023 6/1/2023
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Elicio Therapeutics Inc One Kendall Square CAMBRIDGE MA United States

Business Names
Business Name
Angion Biomedica Europe Limited
Angion PTY LTD
ANGN
4 additional Business Names available in full report.

General Information
Number of Employees: 32 (As of 12/31/2023)
Outstanding Shares: 10,791,326 (As of 11/8/2024)
Shareholders: 245
Stock Exchange: NASD
Federal Tax Id: 113430072
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024